NCT04494724 is a Phase 2 clinical trial of Clazakizumab in COVID-19 Infection, sponsored by The Methodist Hospital Research Institute.

Who is sponsoring NCT04494724?

NCT04494724 is sponsored by The Methodist Hospital Research Institute.

What drugs are being tested in NCT04494724?

Interventions in NCT04494724: Clazakizumab, Placebo.

What condition does NCT04494724 study?

NCT04494724 studies COVID-19 Infection.

Is NCT04494724 still recruiting?

NCT04494724 is currently status unknown. Last updated 31 July 2020.

Last reviewed 2020-07-31 · How we verify

NCT04494724

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clazakizumab vs. Placebo - COVID-19 Infection

Status unknown Phase 2 Last updated 31 July 2020

What this trial tests

Phase 2 trial testing Clazakizumab in COVID-19 Infection in 60 participants. Status unknown.

Timeline

13 July 2020

Primary endpoint
31 December 2020

31 July 2021

Quick facts

Lead sponsor	The Methodist Hospital Research Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	13 July 2020
Primary completion	31 December 2020
Estimated completion	31 July 2021
Sites	1 location across United States

Drugs / interventions tested

Clazakizumab — full drug profile →
Placebo

Conditions studied

COVID-19 Infection — all drugs for COVID-19 Infection →

Sponsor

The Methodist Hospital Research Institute

Who can join

18 and older, any sex, with COVID-19 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effectiveness and safety of treatment with clazakizumab compared to a placebo (inactive substance). We are proposing to try this drug to treat coronavirus disease 2019 (COVID-19) infection. Patients with COVID-19 infection have been shown to have increases in certain inflammatory processes. Clazakizumab is an antibody (immune system protein) that blocks certain inflammatory processes. The treatment plan is to attempt to inhibit or block these inflammatory processes in order to try to limit the damage COVID-19 causes to the lungs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Clazakizumab

Trials testing the same drug.

NCT04381052 — Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection · Phase 2 · terminated
NCT04348500 — Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19) · Phase 2 · completed
NCT04129931 — PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study · Phase 2 · completed
NCT03744910 — Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients · Phase 3 · terminated
NCT03380962 — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for COVID-19 Infection

Currently open trials in the same condition.

NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting

Other The Methodist Hospital Research Institute trials

Trials by the same sponsor.

NCT07048314 — Stem Cells for Erectile Dysfunction Post RALP · Phase 1, PHASE2 · not yet recruiting
NCT07283068 — IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA · NA · not yet recruiting
NCT07218484 — VoiceLove Digital Therapy for Delirium in the ICU · NA · recruiting
NCT07050771 — Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery · Phase 2 · recruiting
NCT07182279 — Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04494724 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Methodist Hospital Research Institute
Last refreshed: 31 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04494724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing